Trial Profile
Multi-centre, Multinational, Open-labelled, Randomised, Parallel, Controlled Trial in Type 2 Diabetic Subjects Inadequately Controlled on Repaglinide, to Compare the Efficacy and Safety of Repaglinide Combined With Bedtime NPH Insulin Versus Twice Daily NPH Insulin
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Insulin suspension isophane (Primary) ; Repaglinide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Novo Nordisk
- 14 Apr 2015 New trial record